4880.T
CellSource Co., Ltd. [4880.T] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
4880.T Stock Summary
In the News
4880.T Financial details
Company Rating
Strong Buy
Market Cap
29.17B
Income
851M
Revenue
4.62B
Book val./share
301.19
Cash/share
236.4
Dividend
15
Dividend %
1.18%
Employees
151
Optionable
No
Shortable
Yes
Earnings
11 Mar 2024
P/E
22.07
Forward P/E
-
PEG
-12.06
P/S
5.23
P/B
5.43
P/C
6.21
P/FCF
-
Quick Ratio
7.95
Current Ratio
8.82
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
44.56
EPS next Y
-
EPS next Q
-
EPS this Y
-10.38%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
33.45%
Revenue last 5Y
22.86%
Revenue Q/Q
6.26%
EPS Q/Q
-43.56%
-
-
-
-
SMA20
4.62%
SMA50
16.36%
SMA100
-7.78%
Inst Own
-
Inst Trans
-
ROA
22%
ROE
27%
ROC
0.37%
Gross Margin
72%
Oper. Margin
35%
Profit Margin
23%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1179.0-3180.0
52W High
-53.87%
52W Low
+24.43%
RSI
53
Rel Volume
0.86
Avg Volume
204.86K
Volume
176.5K
Perf Week
1.45%
Perf Month
3.31%
Perf Quarter
-25.95%
Perf Half Y
-26.28%
-
-
-
-
Beta
0.249
-
-
Volatility
40.44%, 43.22%
Prev Close
-5.42%
Price
1467
Change
0%
4880.T Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-10-31
| Metric | History | 2019-10-31 | 2020-10-31 | 2021-10-31 | 2022-10-31 | 2023-10-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 93.26 | 102.8 | 157.78 | 229.01 | 238.85 | |
| Net income per share | 11.55 | 15.19 | 35.17 | 54.54 | 48.88 | |
| Operating cash flow per share | 11.3 | 18.3 | 48.5 | 45.42 | 44.84 | |
| Free cash flow per share | 8.21 | 16.48 | 45.18 | 40.1 | 25.83 | |
| Cash per share | 77.17 | 97.35 | 130.09 | 167.37 | 253.18 | |
| Book value per share | 93.04 | 113.17 | 146.88 | 202.84 | 328.42 | |
| Tangible book value per share | 92.79 | 112.86 | 146.28 | 202.28 | 327.37 | |
| Share holders equity per share | 93.04 | 113.17 | 146.88 | 202.84 | 328.42 | |
| Interest debt per share | 0.43 | 0.25 | 0.07 | 0 | 5.19 | |
| Market cap | 15.63B | 51.14B | 120.76B | 82.02B | 33.67B | |
| Enterprise value | 14.3B | 49.39B | 118.35B | 78.9B | 28.99B | |
| P/E ratio | 78.3 | 186.58 | 185.38 | 80.58 | 36.47 | |
| Price to sales ratio | 9.7 | 27.56 | 41.32 | 19.19 | 7.46 | |
| POCF ratio | 80.03 | 154.86 | 134.44 | 96.77 | 39.77 | |
| PFCF ratio | 110.16 | 171.89 | 144.32 | 109.59 | 69.04 | |
| P/B Ratio | 9.72 | 25.04 | 44.39 | 21.67 | 5.43 | |
| PTB ratio | 9.72 | 25.04 | 44.39 | 21.67 | 5.43 | |
| EV to sales | 8.87 | 26.62 | 40.5 | 18.46 | 6.43 | |
| Enterprise value over EBITDA | 44.13 | 112.4 | 113.5 | 48.06 | 22.94 | |
| EV to operating cash flow | 73.24 | 149.55 | 131.76 | 93.08 | 34.24 | |
| EV to free cash flow | 100.81 | 166 | 141.44 | 105.42 | 59.44 | |
| Earnings yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 | |
| Free cash flow yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0.02 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0.01 | |
| Net debt to EBITDA | -4.09 | -3.99 | -2.31 | -1.9 | -3.71 | |
| Current ratio | 7.19 | 7.02 | 4.65 | 5.01 | 12.36 | |
| Interest coverage | 6.67K | 1.45K | 7.3K | 142.82K | 3.22K | |
| Income quality | 0.64 | 0.8 | 0.89 | 0.54 | 0.68 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0.01 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.09 | 0.09 | 0.07 | 0.08 | 0.1 | |
| Research and developement to revenue | 0 | 0.01 | 0.02 | 0.02 | 0.02 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | -0.27 | -0.1 | -0.07 | -0.12 | -0.42 | |
| Capex to revenue | -0.03 | -0.02 | -0.02 | -0.02 | -0.08 | |
| Capex to depreciation | -2.58 | -1.25 | -2.01 | -2.18 | -5.62 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0.01 | 0 | |
| Graham number | 155.5 | 196.64 | 340.93 | 498.92 | 601.03 | |
| ROIC | 0.13 | 0.13 | 0.24 | 0.27 | 0.14 | |
| Return on tangible assets | 0.11 | 0.12 | 0.19 | 0.22 | 0.13 | |
| Graham Net | 74.99 | 95.24 | 114.49 | 159.26 | 243.54 | |
| Working capital | 1.42B | 1.86B | 2.31B | 3.26B | 5.14B | |
| Tangible asset value | 1.6B | 2.04B | 2.71B | 3.78B | 6.18B | |
| Net current asset value | 1.42B | 1.86B | 2.3B | 3.26B | 4.91B | |
| Invested capital | 0 | 0 | 0 | 0 | 0.02 | |
| Average receivables | 170.49M | 213.21M | 319.22M | 548.33M | 594.59M | |
| Average payables | 23.05M | 22.25M | 35.45M | 75.36M | 92.58M | |
| Average inventory | 144.25M | 148.65M | 148.94M | 196.28M | 266.47M | |
| Days sales outstanding | 34.53 | 53.89 | 45.52 | 62.53 | 36.98 | |
| Days payables outstanding | 11.66 | 18.28 | 17.66 | 33.1 | 20.78 | |
| Days of inventory on hand | 131.48 | 80.97 | 71.24 | 68.51 | 84.24 | |
| Receivables turnover | 10.57 | 6.77 | 8.02 | 5.84 | 9.87 | |
| Payables turnover | 31.3 | 19.97 | 20.67 | 11.03 | 17.57 | |
| Inventory turnover | 2.78 | 4.51 | 5.12 | 5.33 | 4.33 | |
| ROE | 0.12 | 0.13 | 0.24 | 0.27 | 0.15 | |
| Capex per share | -3.09 | -1.81 | -3.32 | -5.31 | -19.01 |
Quarterly Fundamentals Overview
Last date of statement is 2024-01-31 for Q1
| Metric | History | 2023-01-31 | 2023-04-30 | 2023-07-31 | 2023-10-31 | 2024-01-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 56.7 | 59.43 | 65.39 | 57.36 | 59.29 | |
| Net income per share | 11.56 | 10.38 | 14.03 | 12.88 | 7.27 | |
| Operating cash flow per share | 1.24 | 1.28 | 1.63 | 2.59 | 0 | |
| Free cash flow per share | 1.24 | 1.28 | 1.63 | 2.59 | 0 | |
| Cash per share | 163.33 | 179.79 | 166.49 | 248.3 | 236.4 | |
| Book value per share | 214.37 | 224.74 | 237.5 | 322.1 | 301.19 | |
| Tangible book value per share | 213.86 | 224.28 | 237.08 | 321.07 | 301.19 | |
| Share holders equity per share | 214.37 | 224.74 | 237.5 | 322.1 | 301.19 | |
| Interest debt per share | 0.63 | -0.6 | 0 | 5.09 | 0.02 | |
| Market cap | 67.83B | 47.58B | 41.94B | 34.33B | 24.72B | |
| Enterprise value | 64.78B | 44.22B | 38.8B | 29.65B | 20.11B | |
| P/E ratio | 78.49 | 61.31 | 39.56 | 34.61 | 42.95 | |
| Price to sales ratio | 64.02 | 42.82 | 33.95 | 31.09 | 21.06 | |
| POCF ratio | 2.94K | 2K | 1.36K | 687.54 | 0 | |
| PFCF ratio | 2.94K | 2K | 1.36K | 687.54 | 0 | |
| P/B Ratio | 16.93 | 11.32 | 9.35 | 5.54 | 4.15 | |
| PTB ratio | 16.93 | 11.32 | 9.35 | 5.54 | 4.15 | |
| EV to sales | 61.14 | 39.8 | 31.4 | 26.85 | 17.14 | |
| Enterprise value over EBITDA | 193.77 | 139.04 | 99.75 | 187.36 | 86.88 | |
| EV to operating cash flow | 2.8K | 1.85K | 1.26K | 593.75 | 0 | |
| EV to free cash flow | 2.8K | 1.85K | 1.26K | 593.75 | 0 | |
| Earnings yield | 0 | 0 | 0.01 | 0.01 | 0.01 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0 | 0 | 0 | 0.02 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0.01 | 0 | |
| Net debt to EBITDA | -9.13 | -10.57 | -8.09 | -29.6 | -19.9 | |
| Current ratio | 9.14 | 6.77 | 8.82 | 12.36 | 8.61 | |
| Interest coverage | 29.95 | -27.5 | 0 | 470.41 | 557.89 | |
| Income quality | 0.11 | 0.12 | 0.12 | 0.2 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0.01 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 236.15 | 229.08 | 273.81 | 305.52 | 221.97 | |
| ROIC | 0.06 | 0.04 | 0.05 | 0.04 | 0.02 | |
| Return on tangible assets | 0.05 | 0.04 | 0.05 | 0.04 | 0.02 | |
| Graham Net | 162.34 | 170.13 | 164.27 | 238.85 | 212.17 | |
| Working capital | 3.34B | 3.52B | 3.56B | 5.14B | 4.76B | |
| Tangible asset value | 4B | 4.19B | 4.48B | 6.18B | 5.92B | |
| Net current asset value | 3.34B | 3.52B | 3.48B | 4.91B | 4.54B | |
| Invested capital | 0 | 0 | 0 | 0.02 | 0 | |
| Average receivables | 550.5M | 392.97M | 443.2M | 463.13M | 389.24M | |
| Average payables | 85.26M | 65.92M | 78.53M | 80.75M | 79.62M | |
| Average inventory | 229.4M | 233.14M | 253.9M | 289.61M | 278.88M | |
| Days sales outstanding | 31.33 | 33.79 | 34.18 | 37.24 | 24.66 | |
| Days payables outstanding | 19.55 | 18.37 | 22.33 | 19.36 | 18.41 | |
| Days of inventory on hand | 74.48 | 60.66 | 70.92 | 78.5 | 55.32 | |
| Receivables turnover | 2.87 | 2.66 | 2.63 | 2.42 | 3.65 | |
| Payables turnover | 4.6 | 4.9 | 4.03 | 4.65 | 4.89 | |
| Inventory turnover | 1.21 | 1.48 | 1.27 | 1.15 | 1.63 | |
| ROE | 0.05 | 0.05 | 0.06 | 0.04 | 0.02 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
4880.T Frequently Asked Questions
What is CellSource Co., Ltd. stock symbol ?
CellSource Co., Ltd. is a JP stock and trading under the symbol 4880.T
What is CellSource Co., Ltd. stock quote today ?
CellSource Co., Ltd. stock price is $1467 today.
Is CellSource Co., Ltd. stock public?
Yes, CellSource Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 204.86K
- Market Capitalization 29.17B
- Employee 151
- CEO Mr. Takashi Sawada
- Headquarters Tokyo,JP
- IPO Date 2019-10-29
-
Website
https://www.cellsource.co.jp 
CellSource Co., Ltd. engages in the regenerative medicine-related and consumer businesses. It also offers Signalift, an anti-aging product. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.
